Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Clinical trial NCT02564523 · COMPLETED

Trial details

NCT number: NCT02564523
Sponsor: Janssen Vaccines & Prevention B.V.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hemorrhagic Fever, Ebola

Start date: 2015-11-06
Primary completion: 2019-02-12
Enrollment: 1075

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.